NCT06202066View on ClinicalTrials.gov

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

October 15, 2027

Study Completion Date

October 15, 2028

Conditions

Digestive System Neuroendocrine NeoplasmLung Neuroendocrine NeoplasmMalignant Solid NeoplasmPancreatic Neuroendocrine Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

BIOLOGICAL

Incomplete Freund''s Adjuvant

Given SC

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

SVN53-67/M57-KLH Peptide Vaccine

Given SC

DRUG

Temozolomide

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

lead

Roswell Park Cancer Institute

OTHER

NCT06202066 - Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas | Biotech Hunter | Biotech Hunter